Literature DB >> 5037877

Coagulation studies in patients with acute infectious hepatitis.

A S Gallus, C R Lucas, J Hirsh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5037877     DOI: 10.1111/j.1365-2141.1972.tb05720.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Behaviour of 125I-fibrinogen and 131I-albumin in experimental galactosamine-induced hepatitis.

Authors:  I Mahn; H Merkel; E L Sattler; G Müller-Berghaus
Journal:  Gut       Date:  1977-07       Impact factor: 23.059

2.  Factors XI and XII are low in subjects with liver disease.

Authors:  I R Walker; R A Milner; M A Johnston; C A Rand; P B Neame; J Hirsh
Journal:  Dig Dis Sci       Date:  1983-11       Impact factor: 3.199

3.  Experimental galactosamine-induced hepatitis. Effect of anticoagulant and antifibrinolytic agents on microclot formation.

Authors:  G Müller-Berghaus; C Reuter; U Bleyl
Journal:  Am J Pathol       Date:  1976-02       Impact factor: 4.307

Review 4.  Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.

Authors:  H G Shetty; A G Fennerty; P A Routledge
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

5.  Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9), a biomarker for various pathological conditions, is produced in post-blood collection by fibrinolysis and coagulation factors.

Authors:  Wataru Kikuchi; Motoi Nishimura; Takahisa Kuga; Sachio Tsuchida; Tatsuya Saito; Mamoru Satoh; Kenta Noda; Yoshio Kodera; Takeshi Tomonaga; Fumio Nomura
Journal:  Clin Proteomics       Date:  2016-10-07       Impact factor: 3.988

Review 6.  Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm.

Authors:  Shinya Yamada; Hidesaku Asakura
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.